BUCHANG PHARMA(SH:603858) Sou Hu Cai Jing·2025-05-27 10:45Core Viewpoint - The company is changing the purpose of its 2024 share repurchase plan to reduce registered capital by canceling 6,620,630 shares, reflecting its commitment to shareholder value and social responsibility [1][2]. Group 1: Share Repurchase and Capital Management - The company has repurchased a total of 6.6206 million shares, accounting for 0.60% of its total share capital, with a cumulative repurchase amount of 98.0558 million yuan [2]. - The share repurchase plan aims to enhance shareholder rights and is expected to increase the per-share value by reducing the total share capital from 1.106 billion shares to 1.061 billion shares [2]. Group 2: Social Responsibility and Community Engagement - The company has paid nearly 32 billion yuan in taxes since its establishment, contributing significantly to local economic development and public welfare [3]. - In 2024, the company donated 10 million yuan worth of medical supplies to Ganzi Prefecture and 163 million yuan in medical resources to 148 counties in Tibet, improving grassroots medical conditions [3]. Group 3: Industry Position and Product Development - The company has established a diversified product system centered on traditional Chinese medicine, with significant sales in the cardiovascular sector, achieving a total revenue of 5.830 billion yuan in 2024 from key products [4]. - The company is focusing on innovative research and development, integrating traditional Chinese medicine with modern pharmaceutical practices, and advancing multiple projects in biopharmaceuticals and vaccines [5]. Group 4: Strategic Vision and Market Leadership - The company aims to build a strong competitive edge in the pharmaceutical industry, aspiring to become "China's Johnson & Johnson" and "the world's Buchang" through continuous innovation and market expansion [6].